• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Toolbar - View Selection
 
Items 1 of 1
ALX-270-289 Revised 25-Jun-08
PJ-34
Add to Clipboard
SYNONYMS N-(6-Oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide . HCl
PRODUCT LINE DNA Regulation / Transcription
PRODUCT CATEGORY PARP Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-270-289-M001   1 mg 50.00 USD Add To Cart
ALX-270-289-M005   5 mg 125.00 USD Add To Cart
ALX-270-289-M025   25 mg 375.00 USD Add To Cart
Product Specification
FORMULA: C17H17N3O2 . HCl
MW: 295.2 . 36.5
PURITY: ≥98% (NMR)
APPEARANCE: White to light brown powder.
SOLUBILITY: Soluble in DMSO or water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C
USE/STABILITY: Stable for 2 years after receipt when stored at +4C°. Stock solutions are stable for 3 weeks when stored at room temperature.
HANDLING: Hygroscopic.
IDENTITY: Identity determined by 1H-NMR and MS.

Product Description
Potent, water soluble poly(ADP-ribose) polymerase (PARP) inhibitor (EC50=20nM compared to EC50=200µM of the prototypical PARP inhibitor 3-aminobenzamide (Prod. No. ALX-270-044)). Inhibits peroxynitrite (Prod. No. ALX-400-036)-induced cell necrosis (EC50=20nM). Has significant, dose-dependent, anti-inflammatory effects in a variety of local inflammation models and provides cardioprotection by decreasing myocardial infarct size.
Product Specific Literature References
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke: G.E. Abdelkarim, et al.; Int. J. Mol. Med. 7, 255 (2001) Abstract
Partial protection by poly(ADP-ribose) polymerase inhibitors from nitroxyl-induced cytotoxity in thymocytes: P. Bai, et al.; Free Radic. Biol. Med. 31, 1616 (2001) Abstract
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation: F. Garcia Soriano, et al.; Nat. Med. 7, 108 (2001) Abstract
Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase: J.G. Mabley, et al.; Inflamm. Res. 50, 561 (2001) Abstract
Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor: R. Faro, et al.; Ann. Thorac. Surg. 73, 575 (2002) Abstract
Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents: P. Jagtap, et al.; Crit. Care Med. 30, 1071 (2002) Abstract
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging: P. Pacher, et al.; Int. J. Mol. Med. 9, 659 (2002) Abstract
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure: P. Pacher, et al.; J. Am. Coll. Cardiol. 40, 1006 (2002) Abstract
Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyperdynamic porcine endotoxemia: Z. Ivanyi, et al.; Shock 19, 415 (2003) Abstract; Full Text
General Literature References
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors: L. Virag and C. Szabo; Pharmacol. Rev. 54, 375 (2002), (Review) Abstract
Further Categories Containing This Product:
Non-apoptotic Cell Death / Necrosis • DNA Repair Other Products
 
 
© 2008 ALEXIS Corporation, Privacy Policy, Disclaimer, Feedbackanother CS2 website

Catalogs / Brochures

E-Newsletter

 

Shopping Cart [0]

 

Distributors

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.